ClinicalTrials.gg
Not yet recruitingNCT07557355Updated Jun 5, 2026

A Study of SRSD384 in Overweight or Obese Participants

A Phase 1/2 interventional study of SRSD384 injection and Placebo in Overweight , Obesity, sponsored by Sirius Therapeutics Co., Ltd.. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-05.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sirius Therapeutics Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 188 studies in Obesity with a site in Australia — 56 open to participants now, 74 under way, 34 of them phase 3. Obesity · Australia.

Planned enrollment
108th of 169
78 · median 180
Started
2026
with 40 others
Phase 1/2
5 of 188
3 open now
Primary completion
2027-10
later than 30 of 73 live
Registered
166th of 188
by date

Among the 188 studies in Obesity with a site in Australia, this one is the 108th largest by planned enrollment of the 169 interventional ones that give a count, is one of 41 that started in 2026, is one of 5 in phase 1/2, reaches primary completion later than 30 of the 73 other live ones, and was the 166th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

56 of the 188 studies in Obesity with a site in Australia are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Obesity with a site in Australia, or all of them as a file.
02

Study summary

This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD384 alone in overweight or obese participants (Part A) and in combination with tirzepatide in overweight or obese participants with T2DM (Part B).

03

Conditions studied

  • Overweight , Obesity

Browse trials for

04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 78 is above the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Sirius Therapeutics Co., Ltd. is the lead sponsor of 6 studies on the registry; 4 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to comprehend and willing to sign an form (ICF) and to abide by the study restrictions;
  • Males or females;
  • (BMI) between 27.0 and 40.0 kg/m2, inclusive;
  • Male subjects are not allowed to donate sperm, and female subjects are not allowed to donate eggs from the time the ICF is signed until at least 3 months after the last follow-up.

Exclusion criteria

Exclusion Criteria:

  • Obesity attributable, in the investigator's opinion, to medication use, endocrinologic or monogenic disorders;
  • Having a significant medical history or clinical manifestations related to any allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine (other than overweight or obesity), or psychiatric conditions that are severe or unstable (determined by the investigator or medically qualified designee);
  • Evidence of active cancer within 2 years prior to screening (non-melanoma skin cancer, localized prostate cancer treated with curative intent, or other in situ carcinoma that does not require systemic therapy and is considered cured for at least 1 year is allowed);
  • Acute febrile illness within 7 days prior to randomization or evidence of active infection
  • Any major surgery within 3 months prior to screening or plan to have any major surgery during the study;
  • History of , intolerance, or allergy to any oligonucleotide or GalNAc as determined by the investigator;
  • Receipt of an drug within 30 days or 5 half-lives of that drug, whichever is longer, prior to dose administration in this study;
  • Have previously completed or withdrawn from this study or any other study investigating SRSD384 and have previously received SRSD384.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    SRSD384 injection (Part A)

    Drug: SRSD384 injection

  • Placebo comparator
    0.9% Sodium Chloride (Part A)

    Drug: Placebo

  • Experimental
    SRSD384 injection (Part B)

    Drug: SRSD384 injection

  • Placebo comparator
    0.9% Sodium Chloride (Part B)

    Drug: Placebo

Interventions

  • DrugSRSD384 injection

    Administered S.C. per the protocol

  • DrugPlacebo

    Administered S.C. per the protocol

07

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: 168 days

Secondary outcomes

  1. Maximal concentration of SRSD384

    Time frame: 48 hours

  2. Area under the concentration-time curve from time 0 to infinity of SRSD384

    Time frame: 48 hours

  3. Time to the maximal concentration of SRSD384

    Time frame: 48 hours

08

Study locations

1 site
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Oct 2027, 16 months later.

Of 62 phase 1/2 interventional studies under Obesity, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
Apr 29, 2026
StartEst.
Jun 2026
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07557355
Lead sponsor
Sirius Therapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Apr 29, 2026
Start date
Jun 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Jun 5, 2026

Study contacts

Medical Director
Contact
medical@siriusrna.com
+86 21 61207756
Medical Director
Contact

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion